65620-13-5Relevant articles and documents
Discovery of a potent analgesic NOP and opioid receptor agonist: Cebranopadol
Schunk, Stefan,Linz, Klaus,Hinze, Claudia,Frormann, Sven,Oberb?rsch, Stefan,Sundermann, Bernd,Zemolka, Saskia,Englberger, Werner,Germann, Tieno,Christoph, Thomas,K?gel, Babette-Y.,Schr?der, Wolfgang,Harlfinger, Stephanie,Saunders, Derek,Kless, Achim,Schick, Hans,Sonnenschein, Helmut
, p. 857 - 862 (2014/09/29)
In a previous communication, our efforts leading from 1 to the identification of spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amine 2a as analgesic NOP and opioid receptor agonist were disclosed and their favorable in vitro and in vivo pharmacological properties revealed. We herein report our efforts to further optimize lead 2a, toward trans-6′-fluoro-4′, 9′-dihydro-N,N-dimethyl-4-phenyl-spiro[cyclohexane-1,1′(3′H) -pyrano[3,4-b]indol]-4-amine (cebranopadol, 3a), which is currently in clinical development for the treatment of severe chronic nociceptive and neuropathic pain.
Phencyclidine compounds and assays for its determination
-
, (2008/06/13)
Novel oxime derivatives of phencyclidine are provided as precursors for conjugating proteins, either antigenic for the preparation of antibodies or enzymatic for the preparation of enzyme conjugates, which antibodies and enzyme conjugates find use as reagents in immunoassays. The combination of antibodies and enzyme conjugates provide for sensitive, accurate, rapid assays for phencyclidine without interference from commonly administered drugs, such as dextromethorphan, demerol and chlorpromazine.